More Confidence. More Results.
The Enhanced LSA assay demonstrates a lower false positive rate—increasing your ability to find acceptable donors and providing new beginnings for more transplant patients. With added coverage and specificity, our test is designed for you, to improve operational efficiencies and workflow.

LIFECODES
Single Antigen
Class I & Class II

Ensure Confidence in your Results

• Additional Antigens
Class I & Class II antigen panels provide a more complete antibody profile

• 20:40 Serum to Beads ratio option
Higher MFI values, especially in the 1,000 - 5,000 MFI range

• Simplified Calculation
Increases sensitivity & reproducibility

• Vacuum manifold wash technique reduces total hands-on time, operator variation, and contamination risk

Streamlined Data Analysis

The MATCH IT! software suite was designed specifically as accessory to assist in the evaluation of test results from the LIFECODES Antibody products.

• Built In Epitope Tail Analysis
• Advanced highlight and overlay tools to help determine antibody specificity
• Multiple Graphing features
• Various Reporting Options and Formats
• Automatic import of data into MATCH IT!® software - allowing for clear and easy results interpretation

“Through advances in our manufacturing processes, the current Immucor single antigen panel contains very little denatured antigen.”
- Bryan Ray, PhD, Immucor

Denatured antigen is the #1 cause of false positive Single Antigen results. It has been demonstrated that Immucor’s LSA beads contain “exclusively” the clinically relevant native HLA-I antigen. The minimal amount of denatured antigen on the single antigen beads makes the Immucor LIFECODES® Single Antigen Assay an ideal method for resolving false positives.
The LIFECODES C3d Assay provides a measure of the binding and processing of complement to one of its end products - C3d. When combined with our LIFECODES LSA™ Single Antigen Kits, the assay offers a simple method for the detection of complement binding to HLA antibodies. Assessment of C3d fixing as part of prospective HLA monitoring can potentially aid stratification of patients at the highest risk of long-term renal allograft dysfunction.  

“New findings now show that the presence of C3d-binding donor specific anti-HLA antibodies (DSAs) at the time of AMR strongly predicts kidney allograft loss and may enable accurate risk stratification of these patients.”

The LIFECODES LSA-MIC kit is designed to detect antibodies directed against MICA antigens. Publications have suggested that anti-MICA antibodies may play a role in the failure of renal allografts.

“MICA antibodies are significantly and independently associated with reduced graft survival in donor graft, providing strong evidence for the involvement of these antibodies with graft rejection.”

- Extensive representation of MICA antigens provides almost 2x the coverage compared to other kits
- Majority of the immunogenic epitopes are present on multiple antigens
- Proprietary manufacturing processes reduce non-specific reactivity thus resulting in fewer false positive reactions

[MICA antigens table]

Highlighted antigens represent unique coverage

---

Please contact your Immucor Sales Representative to schedule a LIFCODES assay demonstration.